Literature DB >> 1337261

The effect of i.v. sumatriptan, a selective 5-HT1-receptor agonist on central haemodynamics and the coronary circulation.

P D Macintyre1, B Bhargava, K J Hogg, J D Gemmill, W S Hillis.   

Abstract

1. Sumatriptan (GR43175) is a selective 5-HT1-receptor agonist effective in the acute treatment of migraine. Vasoactive properties in other vascular beds have been suggested by recent in vitro studies. 2. Its effects on coronary artery dimensions and central haemodynamics were assessed in 10 patients undergoing diagnostic coronary arteriography using digital subtraction angiography and invasive haemodynamic monitoring. 3. Following a 10 min i.v. infusion of sumatriptan to a total dose of 48 micrograms kg-1 there was a significant increase (P < 0.05) in systemic and pulmonary arterial pressures. There was a significant reduction in coronary artery diameter from 4.3 +/- 1.6 mm to 3.6 +/- 1.6 mm 12.9 +/- 6.9% (P < 0.001). There was no significant change in heart rate or ECG morphology. 4. Sumatriptan, a 5-HT1-receptor agonist, causes a vasopressor response in the systemic and pulmonary arterial circulations and coronary artery vasoconstriction; in this study there were no clinical sequelae.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1337261      PMCID: PMC1381457     

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

1.  The selective closure of feline carotid arteriovenous anastomoses (AVAs) by GR43175.

Authors:  M J Perren; W Feniuk; P P Humphrey
Journal:  Cephalalgia       Date:  1989       Impact factor: 6.292

2.  Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist.

Authors:  H E Connor; W Feniuk; P P Humphrey
Journal:  Br J Pharmacol       Date:  1989-02       Impact factor: 8.739

3.  Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan.

Authors:  L Friberg; J Olesen; H K Iversen; B Sperling
Journal:  Lancet       Date:  1991-07-06       Impact factor: 79.321

4.  Influence of the endothelium on contractile effects of 5-hydroxytryptamine and selective 5-HT agonists in canine basilar artery.

Authors:  H E Connor; W Feniuk
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

5.  The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs.

Authors:  W Feniuk; P P Humphrey; M J Perren
Journal:  Br J Pharmacol       Date:  1989-01       Impact factor: 8.739

6.  5-Hydroxytryptamine receptor profile in healthy and diseased human epicardial coronary arteries.

Authors:  A H Chester; G R Martin; M Bodelsson; B Arneklo-Nobin; S Tadjkarimi; K Tornebrandt; M H Yacoub
Journal:  Cardiovasc Res       Date:  1990-11       Impact factor: 10.787

7.  Initial clinical experience with the use of subcutaneous GR43175 in treating acute migraine.

Authors:  N Brion; J Bons; J Plas; E M Bayliss; C Advenier
Journal:  Cephalalgia       Date:  1989       Impact factor: 6.292

8.  5-Hydroxytryptamine contracts human coronary arteries predominantly via 5-HT2 receptor activation.

Authors:  H E Connor; W Feniuk; P P Humphrey
Journal:  Eur J Pharmacol       Date:  1989-02-14       Impact factor: 4.432

9.  Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin.

Authors:  T M Cocks; J A Angus
Journal:  Nature       Date:  1983 Oct 13-19       Impact factor: 49.962

10.  Effect of intracoronary serotonin on coronary vessels in patients with stable angina and patients with variant angina.

Authors:  E P McFadden; J G Clarke; G J Davies; J C Kaski; A W Haider; A Maseri
Journal:  N Engl J Med       Date:  1991-03-07       Impact factor: 91.245

View more
  18 in total

1.  Changes in systolic time intervals-a non-invasive marker for the haemodynamic effects of sumatriptan.

Authors:  S Hood; D Birnie; L S Murray; P D MacIntyre; W S Hillis
Journal:  Br J Clin Pharmacol       Date:  1999-09       Impact factor: 4.335

Review 2.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

3.  Effects of sumatriptan and eletriptan on diseased epicardial coronary arteries.

Authors:  Christopher M H Newman; Ian Starkey; Nigel Buller; Ricardo Seabra-Gomes; Simon Kirby; Jayasena Hettiarachchi; David Cumberland; William S Hillis
Journal:  Eur J Clin Pharmacol       Date:  2005-09-08       Impact factor: 2.953

4.  Augmented contraction of the human isolated coronary artery by sumatriptan: a possible role for endogenous thromboxane.

Authors:  A Maassen VanDenBrink; W A Bax; M D Ferrari; F J Zijlstra; E Bos; P R Saxena
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

5.  Evidence for 5-HT1-like receptor-mediated vasoconstriction in human pulmonary artery.

Authors:  M R MacLean; R A Clayton; A G Templeton; I Morecroft
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

6.  Influence of the endothelium, nitric oxide and serotonergic receptors on coronary vasomotor responses evoked by ergonovine in conscious dogs.

Authors:  D Karila-Cohen; E Delpy; J L Dubois-Randé; L Puybasset; L Hittinger; J F Giudicelli; A Berdeaux
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

7.  Adverse reactions attributed to sumatriptan. A postmarketing study in general practice.

Authors:  J P Ottervanger; T B van Witsen; H A Valkenburg; D E Grobbee; B H Stricker
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

8.  Comparison of contractile responses to 5-hydroxytryptamine and sumatriptan in human isolated coronary artery: synergy with the thromboxane A2-receptor agonist, U46619.

Authors:  T M Cocks; B K Kemp; D Pruneau; J A Angus
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

9.  A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro.

Authors:  A Ferro; J Longmore; R G Hill; M J Brown
Journal:  Br J Clin Pharmacol       Date:  1995-09       Impact factor: 4.335

Review 10.  Pulmonary hypertension: therapeutic targets within the serotonin system.

Authors:  Y Dempsie; M R MacLean
Journal:  Br J Pharmacol       Date:  2008-06-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.